16 results match your criteria bortezomib myelomatous

  • Page 1 of 1

Isolated third cranial nerve palsy as the first presentation of multiple myeloma.

BMJ Case Rep 2021 Mar 24;14(3). Epub 2021 Mar 24.

Department of Hematology, All India Institute of Medical Sciences, New Delhi, Delhi, India.

A 50-year-old woman presented with a right-sided isolated third cranial nerve palsy. MRI brain showed a mass lesion arising from the right clivus with extension into the cavernous sinus. Blood investigations and bone marrow biopsy were suggestive of multiple myeloma with hypercalcaemia and renal dysfunction. Read More

View Article and Full-Text PDF

[Successful treatment of myelomatous pleural effusion with daratumumab administration before autologous peripheral stem cell transplantation].

Rinsho Ketsueki 2020 ;61(8):879-884

Department of Hematology, Toyama University Hospital.

A 50-year-old woman diagnosed with surgically resected plasmacytoma of the ovaries and uterus presented with another plasmacytoma in the pancreas with positive uptake on positron emission tomography (PET) and massive right pleural effusion with plasma cell infiltration (myelomatous pleural effusion). After four courses of the bortezomib, lenalidomide, and dexamethasone regimen as induction therapy, partial response was achieved with reduced myelomatous pleural effusion and negative uptake on PET in the pancreatic plasmacytoma. However, soon after she received bortezomib and high-dose cyclophosphamide for peripheral blood stem cell harvesting, right myelomatous pleural effusion increased without signs of heart failure or infection. Read More

View Article and Full-Text PDF
October 2020

Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement.

Clin Case Rep 2017 08 22;5(8):1258-1260. Epub 2017 Jun 22.

Haematology Department Santa Lucía University General Hospital Cartagena Spain.

The dismal outcome of pleuropericardial extramedullary multiple myeloma (EMM) reflects both the selection of resistant disease and absence of useful drugs. Carfilzomib and dexamethasone should be explored in advanced EMM patients, even for bortezomib-resistant patients, as may provide much longer overall survival than previously reported treatments. Read More

View Article and Full-Text PDF

Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma.

Clin Radiol 2017 Oct 3;72(10):850-857. Epub 2017 Jun 3.

Hematology and Clinical Immunology Section, Department of Medicine DIMED, University-Hospital of Padua, Italy.

Aim: To evaluate the modifications of the apparent diffusion coefficient (ADC) in myelomatous lesions before and after induction treatment and the correlation with patient response to therapy according to International Myeloma Working Group (IMWG) criteria.

Materials And Methods: A homogeneous group of 18 patients with a diagnosis of symptomatic multiple myeloma who underwent whole-body MRI with diffusion-weighted imaging (DWI-MRI) before and after bortezomib-based induction chemotherapy were evaluated prospectively. Quantitative analysis of ADC maps of myelomatous lesions was performed with the following pattern types: focal pattern, diffuse pattern (moderate and severe), and "salt and pepper" pattern. Read More

View Article and Full-Text PDF
October 2017

Solitary pleural myeloma diagnosed by semi-rigid thoracoscopy: A case report and literature review.

Mol Clin Oncol 2016 Nov 23;5(5):532-536. Epub 2016 Aug 23.

Department of Respiratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China.

Multiple myeloma (MM) is characterized by abnormal proliferation of neoplastic plasma cells. Pleural effusion as an initial presentation of this disease is rare, as is true pleural myeloma. We herein present a case of solitary pleural myelomatous lesion in a 70-year-old male patient diagnosed by pleural biopsy via semi-rigid thoracoscopy followed by histopathological examination. Read More

View Article and Full-Text PDF
November 2016

Flow Cytometry in Diagnosis of Myelomatous Pleural Effusion: A Case Report.

Indian J Hematol Blood Transfus 2016 Jun 3;32(Suppl 1):138-42. Epub 2015 Sep 3.

Department of Medical Oncology, Dr BRA IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

Plasma cell myeloma is a multifocal plasma cell neoplasm associated with increased monoclonal protein in serum and/or urine. Pleural effusions in patients with myeloma are uncommon (6 %). However, effusions due to direct infiltration of the pleura by plasma cells (myelomatous pleural effusion) are extremely rare (<1 %) and usually seen with IgA myeloma. Read More

View Article and Full-Text PDF

Myelomatous pleural effusion involvement in 23 patients with multiple myeloma: A single-center clinical analysis.

Thorac Cancer 2015 May 15;6(3):359-62. Epub 2015 Jan 15.

Department of Health, Beijing Friendship Hospital, Capital Medical University Beijing, China.

We investigated the treatment and prognosis of pleural effusion (PE) in multiple myeloma (MM) patients. From June 2005 to December 2013, 296 MM patients participated in this study. There were 23 PE patients, including 11 men and 12 women, with a median age of 56. Read More

View Article and Full-Text PDF

Polyclonal serum IgM level identifies a subgroup of multiple myeloma patients with low-risk clinicobiological features and superior survival.

Leuk Res 2014 Jun 13;38(6):666-72. Epub 2014 Mar 13.

State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, People's Republic of China. Electronic address:

Normal plasma cells (PCs) are either undetectable or outnumbered by the myelomatous PC compartment in bone marrow of multiple myeloma (MM). However, residual normal PCs have been detected in a minority of symptomatic MM patients with superior survival. The number of normal PCs is also an important factor to identify monoclonal gammopathy of undetermined significance (MGUS)-like MM. Read More

View Article and Full-Text PDF

Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL.

Cancer Cell Int 2013 Dec 12;13(1):122. Epub 2013 Dec 12.

Department of Medicine, Queen Mary Hospital, University of Hong Kong, Room 419, Block K Pokfulam Road, Hong Kong, Hong Kong.

Background: A new human myeloma cell line, MMLAL, was established from the myelomatous pleural effusion of a 73-year-old Chinese patient suffering from symptomatic International stage III IgG/lambda myeloma. After a brief period of complete remission, he developed aggressive systemic relapse complicated by malignant pleural effusion with exclusive plasma cell infiltration. His disease remained chemo-refractory, and died six months after relapse. Read More

View Article and Full-Text PDF
December 2013

Intrapleural bortezomib for the therapy of myelomatous pleural effusion: a case report.

Case Reports Immunol 2012 11;2012:978479. Epub 2012 Oct 11.

1st Department of Medicine and Clinical Department of Hematology, the General Teaching Hospital, Charles University in Prague, Prague, Czech Republic.

Myelomatous pleural effusion (MPE) is an extremely rare manifestation of multiple myeloma (MM). We present a case of MPE in a patient with IgG-κ MM treated with intrapleural bortezomib with systemic bortezomib-based therapy. Although we observed good local response, the patient succumbed due to systemic myeloma progression. Read More

View Article and Full-Text PDF
November 2014

Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.

Ann Hematol 2012 Feb 1;91(2):257-69. Epub 2011 Jul 1.

Centro de Investigación del Cáncer, IBMCC (CSIC-Universidad de Salamanca), Salamanca, Spain.

Despite the advantage observed with novel drugs such as bortezomib, thalidomide, or lenalidomide, multiple myeloma (MM) remains incurable and there is a clear need for new drugs or combinations based on the pathogenetic mechanism of MM. One of the proposed mechanisms in MM pathogenesis is the involvement of kinase molecules in the growth and survival of myelomatous cells. In this study, we have explored the optimal combination for dasatinib, a tyrosine kinase inhibitor, in MM cells. Read More

View Article and Full-Text PDF
February 2012

Osteoblastogenesis and tumor growth in myeloma.

Shmuel Yaccoby

Leuk Lymphoma 2010 Feb;51(2):213-20

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

Myeloma is associated with suppression of osteoblastogenesis, consequentially resulting in increased osteoclast activity and induction of typical osteolytic bone disease. The molecular mechanisms by which myeloma cells suppress osteoblastogenesis and the consequences of increased osteoblast activity on myeloma cell growth have been partially delineated only recently. Reduced osteoblastogenesis is a consequence of abnormal properties and impaired osteogenic potential of osteoprogenitor cells from myeloma patients and is also the result of production of multiple osteoblastogenesis inhibitors by myeloma cells and by microenvironmental cells within the myelomatous bone. Read More

View Article and Full-Text PDF
February 2010

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.

Am J Hematol 2009 Jan;84(1):6-14

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

Multiple myeloma (MM), a hematologic malignancy of terminally differentiated plasma cells is closely associated with induction of osteolytic bone disease, induced by stimulation of osteoclastogenesis and suppression of osteoblastogenesis. The ubiquitin-proteasome pathway regulates differentiation of bone cells and MM cell growth. The proteasome inhibitor, bortezomib, is a clinical potent antimyeloma agent. Read More

View Article and Full-Text PDF
January 2009

Role of decorin in the antimyeloma effects of osteoblasts.

Blood 2008 Jul 24;112(1):159-68. Epub 2008 Apr 24.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

Building on our previous report that osteoblasts and increased bone formation have a negative impact on myeloma cell growth in a subset of patients, we investigated the role of decorin, the main small leucine-rich proteoglycan (SLRP) expressed and produced by osteoblasts, in the antimyeloma effects of osteoblasts. In coculture experiments with osteoblasts, primary myeloma cell survival was significantly higher when decorin expression in osteoblasts was knocked down by short-hairpin RNA. Coculture experiments of myeloma cells and supporting osteoclasts in the presence of osteoblast-conditioned medium showed reduced myeloma cell survival, an effect that was attenuated by decorin-neutralizing antibody. Read More

View Article and Full-Text PDF

Multifunctional role of Erk5 in multiple myeloma.

Blood 2005 Jun 3;105(11):4492-9. Epub 2005 Feb 3.

Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Spain.

Multiple myeloma is characterized by the accumulation of terminally differentiated B cells in the bone marrow, due to increased proliferation and restricted apoptosis of the myelomatous clone. Here we have studied the participation of a novel mitogen-activated protein kinase (MAPK) route, the extracellular signal-regulated kinase 5 (Erk5) pathway, in the regulation of myeloma cell proliferation and apoptosis. Erk5 was expressed in cells isolated from patients and in myeloma cell lines. Read More

View Article and Full-Text PDF
  • Page 1 of 1